Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. BOSTON, Oct.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Synlogic, Inc. SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

DECEMBER 18, 2020

18, 2020 — Allergic reactions to vaccines are generally rare and people with common allergies are not more likely to have a reaction to the Pfizer-BioNTech COVID-19 vaccine, according to guidance released by the American College of Allergy, Asthma & Immunology (ACAAI). © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec. Source link.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 12, 2020

12, 2020 — Lung cancer patients who harbor certain bacteria in the airways may have a poorer prognosis, a new study finds, adding to evidence that the body’s “microbiome” may play a role in cancer patients’ outlook. © 2020 HealthDay. Posted: November 2020. THURSDAY, Nov. All rights reserved.

Immune Response 52

Immune Response Research Doctors Treatment 52

The Pharma Data

JUNE 25, 2021

CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. The quality of the immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ 2020 Apr 9;72(9):1435–46. doi: 10.1002/art.41275.

Immune Response 52

Immune Response Trials Treatment Disease 52

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The agreement was first expanded in March 2020 to include development of a novel mRNA vaccine for COVID-19. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Taken together, these factors suggest that Annamycin could represent an important treatment to help address a significant unmet need in patients with STS lung metastases. . .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 06:00 UTC. Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data).

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

DECEMBER 23, 2020

24, 2020 07:00 UTC. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 02:48 UTC. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc. Coordinating Investigator of the trial commented, “IP-001 combines the promise of modern immunotherapy with the trend towards intratumoral treatment. SAKK is excited to bring this novel treatment to patients in desperate need for new innovative treatment options.”.

Clinical Trials 40

Clinical Trials Immune Response Trials Clinical Development 40

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer BioNTech COVID-19 Vaccine. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. . PLYMOUTH MEETING, Pa. , Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g.,

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Adicet Bio, Inc. T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20 for treatment of non-Hodgkin’s lymphoma (NHL). ADI-001 is an investigational allogeneic gamma delta T cell therapy being developed as a treatment for B-cell non-Hodgkin’s lymphoma (NHL). and BOSTON, Oct.

FDA 40

FDA Immune Response Clinical Trials Engineering 40

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. They found that COVID-19 patients taking indomethacin were less likely than those taking an anti-inflammatory that doesn’t target PGES-2 to require treatment at a hospital. 2020 Oct 15:eabe9403.

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

JANUARY 31, 2021

While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. “We This press release features multimedia. View the full release here: [link]. Terms of the Agreement.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 10, 2020

We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. Tiziana Life Sciences January 9, 2020 Press Release ( [link] ). . Crohn’s Disease Therapeutics Market Size $4.7 Billion by 2025. NEW YORK and LONDON, Nov.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

SEPTEMBER 9, 2020

producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFN? billion doses by the end of 2021. Pfizer Disclosure Notice.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 /PRNewswire/ — Moleculin Biotech , Inc., There is an extreme unmet need for a more effective treatment of sarcomas that have metastasized to the lungs, and we intend for this to be a primary focus of our next IND for Annamycin. . HOUSTON , Oct. Moleculin Biotech, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Treatment Immune Response 40

The Pharma Data

JANUARY 17, 2021

By exploring multiple therapies across oncology and cardiovascular, genetic, neurological and autoimmune diseases, we are well positioned to bring life-changing treatments to multiple patient populations with critical unmet needs.”. A total of $15.4 References 1.

Therapies 40

Therapies Clinical Trials Disease Immune Response 40

The Pharma Data

AUGUST 20, 2020

These results informed the selection of the BNT162b2 candidate for the pivotal Phase 2/3 global study in up to 30,000 participants that started in July 2020, which has to date enrolled more than 11,000 participants, including in areas with significant SARS-CoV-2 transmission. billion doses by the end of 2021. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. The human monoclonal antibody targets specific immune plasma cells. Treatment induced sustainable clinical responses and reduced systemic inflammation.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JUNE 25, 2021

A Variant of Concern (VoC) is defined as a variant for which there is evidence of an increase in transmissibility, more severe disease, significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures. About PREVENT-19.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

FEBRUARY 18, 2022

“For clinicians treating patients with this serious, chronic disease, results from the True North extension study provide an understanding of long-term therapeutic outcomes and help to identify an appropriate treatment approach for their patients with ulcerative colitis,” said Silvio Danese, M.D., About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Treatment Immune Response Disease 40

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

NOVEMBER 14, 2020

November 15, 2020 — The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. Posted: November 2020.

Clinical Trials 40

Clinical Trials Vaccine Trials Pharmaceutical Companies 40

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. The Company expects topline data in the Phase 3 RELIEF study in the fourth quarter of 2020. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation. CHATHAM, N.J.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 11, 2020

Friday, December 11, 2020. Government to supply doses in 2020 & 2021. In July 2020, Pfizer and BioNTech announced an agreement with the HHS and the DoD to meet the U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

NOVEMBER 9, 2020

9, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma. THOUSAND OAKS, Calif. ,

Trials 52

Trials Production Clinical Trials Government 52